Browse Category

NYSE:NVS News 27 June 2025 - 27 October 2025

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

Stock Performance & Recent Trends Prior to the buyout news, RNA stock had been on a steady uptrend in 2025. The share price more than doubled from the low-$20s a year ago to the high-$40s this month ts2.tech. In the past three months alone, RNA jumped ~40%, fueled by upbeat clinical updates and M&A speculation ts2.tech. The stock hit a 52-week peak of $56 in early October ts2.tech after its lead DMD therapy showed strong results and secured FDA Breakthrough designation. Shares pulled back slightly to around $49 by late October, but remained up 100%+ year-over-year ts2.tech. A major catalyst
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

A One‑Time Brain Gene Therapy Just Slowed Huntington’s by 75%—Is This the Turning Point Families Have Waited For?

Key facts (quick read) In‑depth report 1) Huntington’s disease, in plain English What it is. HD is a progressive brain disorder that typically begins in mid‑adulthood, causing a mix of movement (chorea, dystonia), cognitive (processing speed, executive function) and psychiatric symptoms (depression, irritability). It is uniformly fatal over years to decades.  NIH Neurological Institute+1 Genetics. HD is autosomal dominant: each child of an affected parent has a 50% chance to inherit the expansion. The disease is caused by CAG repeat expansion in HTT: ≥40 repeats almost always cause disease in a normal lifespan; 36–39 have reduced penetrance; 27–35 are intermediate (no disease in the carrier but potential expansion in offspring). Anticipation—earlier onset in successive generations—occurs, especially with paternal
Tariff Shocks & Rate Jitters Ignite Wild 48 Hours in European Markets

Tariff Shocks & Rate Jitters Ignite Wild 48 Hours in European Markets

Key Facts German DAX index graph at the Frankfurt Stock Exchange, reflecting volatile mid-week trading reuters.com. Pan-European Overview: From Slump to Rebound European equities seesawed over the two days, buffeted by transatlantic trade tensions and shifting rate expectations. On Thursday Sept. 25, the STOXX Europe 600 index dropped 0.7%, touching levels not seen in three weeks reuters.com. Almost every major bourse closed in the red reuters.com as traders digested a slew of worrying signals: fresh U.S. trade investigations into high-tech imports, surprisingly robust U.S. economic data, and guarded comments from central bankers. By Friday Sept. 26, however, markets regained footing
26 September 2025
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Richmond’s New Pharma Giant: Overview of Lilly’s $5B Factory Eli Lilly’s forthcoming Richmond-area factory is set to be one of the largest and most advanced pharmaceutical manufacturing sites in the world. At a cost of $5 billion, Lilly will construct a high-tech production campus in Goochland County’s West Creek Business Park, a site that had been prepped for a previous project and now deemed “the perfect spot” for fast construction washingtonpost.com. The facility’s core mission: make more of the critical drug ingredients that Lilly usually sources overseas, right here on U.S. soil washingtonpost.com washingtonpost.com. Scale and Scope: The plant will
16 September 2025
Undersea Cable Chaos, iPhone 17 “Air” Reveal & $500B Cloud Bombshell – The Biggest Tech News (Sept 9–10, 2025)

Undersea Cable Chaos, iPhone 17 “Air” Reveal & $500B Cloud Bombshell – The Biggest Tech News (Sept 9–10, 2025)

Consumer Electronics: Apple Unveils Ultra-Thin iPhone 17 Air and More Apple’s latest devices on display at the September 9 launch event in Cupertino. Apple introduced its 2025 lineup of devices at a splashy Cupertino event. Leading the announcements was the iPhone 17 Air, Apple’s thinnest phone ever at just 5.6 mm reuters.com. This new “Air” model (starting at $999) slots between the base iPhone 17 and the Pro flagships as a premium mid-tier option reuters.com. Despite its slim build, it packs the same high-end A19 Pro processor as the Pro, and Apple execs touted it as offering “MacBook Pro levels of compute in an
10 September 2025
Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

Breakthroughs in Biotech & Pharma Big Deals & Industry Moves Regulatory & Health Policy Updates Public Health Developments Noteworthy Medical Research Healthcare Technology & Innovation Sources: Official press releases, government health agency updates, and reputable media coverage were used in this report (including Reuters, Fierce Biotech/Pharma, Bloomberg, FDA/CDC/DSHS releases, and peer-reviewed journals). All source links are provided inline above for reference.
14 August 2025
Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Late 2024, the first FDA-approved CRISPR-based therapy exagamglogene autotemcel (Casgevy) reached patients, with Vertex reporting $2 million in revenue from this sickle-cell gene-editing therapy in Q3 2024. Prime Medicine’s PM359 autologous CRISPR prime-edited cell therapy for chronic granulomatous disease began a Phase I/II study in 2024, with initial first-in-human data expected in late 2025. Wave Life Sciences’ RNA base-editing drug WVE-006 showed proof-of-mechanism in humans in 2024, and multi-dose trial data are anticipated in 2025. In April 2025, the FDA approved Abeona Therapeutics’ Zevaskyn, the first cell-based gene therapy for the rare skin disorder RDEB, with launch planned in Q3
Go toTop